RITUXIMAB-ARRX
Manufacturer: Amgen Inc
Score: 144.0
Riabni (rituximab-arrx) is a CD20-directed cytolytic antibody used for the treatment of adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). It works by targeting the CD20 antigen on B-cells, leading to their depletion. The drug has shown efficacy in various clinical trials, but it also carries important safety warnings, including the risk of fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy. Dosing recommendations vary by condition, and special considerations are needed for certain populations, such as pregnant women, nursing mothers, pediatric patients, and geriatric patients.
Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy
Dose adjustments may be necessary in certain situations, such as in patients with renal or hepatic impairment
375 mg/m^2 as an intravenous infusion according to the following schedules
Not established
375 mg/m^2 the day prior to the initiation of FC chemotherapy, then 500 mg/m^2 on Day 1 of cycles 2-6
Not established
Two 1000 mg intravenous infusions separated by 2 weeks
Not established
375 mg/m^2 once weekly for 4 weeks
Not established